Generic Vyvanse Availability
Last updated on Jul 6, 2022.
Vyvanse is a brand name of lisdexamfetamine, approved by the FDA in the following formulation(s):
VYVANSE (lisdexamfetamine dimesylate - capsule;oral)
-
Manufacturer: TAKEDA PHARMS USA
Approval date: February 23, 2007
Strength(s): 30MG [RLD], 50MG [RLD], 70MG [RLD] -
Manufacturer: TAKEDA PHARMS USA
Approval date: December 10, 2007
Strength(s): 20MG [RLD], 40MG [RLD], 60MG [RLD] -
Manufacturer: TAKEDA PHARMS USA
Approval date: October 30, 2014
Strength(s): 10MG [RLD]
VYVANSE (lisdexamfetamine dimesylate - tablet, chewable;oral)
-
Manufacturer: TAKEDA PHARMS USA
Approval date: January 28, 2017
Strength(s): 10MG [RLD], 20MG [RLD], 30MG [RLD], 40MG [RLD], 50MG [RLD], 60MG [RLD]
Has a generic version of Vyvanse been approved?
No. There is currently no therapeutically equivalent version of Vyvanse available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Vyvanse. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Abuse-resistant amphetamine compounds
Patent 7,105,486
Issued: September 12, 2006
Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Rob & Piccariello; Thomas
Assignee(s): New River Pharmaceuticals Inc.The invention describes compounds, compositions and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
Patent expiration dates:
- February 24, 2023✓
- February 24, 2023✓
- August 24, 2023✓
- February 24, 2023
-
Abuse resistant lysine amphetamine compounds
Patent 7,223,735
Issued: May 29, 2007
Inventor(s): Mickle; Travis & Krishnan; Suma & Moncrief; James Scott & Lauderback; Christopher & Bishop; Barney & Oberlender; Rob & Piccariello; Thomas
Assignee(s): New River Pharmaceuticals Inc.The present invention describes compounds, compositions and methods of using the same comprising lysine covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
Patent expiration dates:
- February 24, 2023✓
- August 24, 2023✓
- February 24, 2023
-
Abuse-resistant amphetamine prodrugs
Patent 7,655,630
Issued: February 2, 2010
Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Robert & Piccariello; Thomas & Paul; Bernhard J. & Verbicky; Christopher A.
Assignee(s): Shire LLCThe invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
Patent expiration dates:
- February 24, 2023✓
- February 24, 2023✓✓
- August 24, 2023✓
- February 24, 2023
-
Abuse-resistant amphetamine prodrugs
Patent 7,659,253
Issued: February 9, 2010
Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Robert & Piccariello; Thomas & Paul; Bernhard J. & Verbicky; Christopher A.
Assignee(s): Shire LLCThe invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
Patent expiration dates:
- February 24, 2023✓✓✓
- August 24, 2023✓
- February 24, 2023
-
Abuse-resistant amphetamine prodrugs
Patent 7,659,254
Issued: February 9, 2010
Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Robert & Piccariello; Thomas & Paul; Bernhard J. & Verbicky; Christopher A.
Assignee(s): Shire LLCThe invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
Patent expiration dates:
- February 24, 2023✓
- February 24, 2023✓
- August 24, 2023✓
- February 24, 2023
-
Abuse resistant lysine amphetamine compounds
Patent 7,662,787
Issued: February 16, 2010
Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Rob & Piccariello; Thomas & Paul; Bernhard J. & Verbicky; Christopher A.
Assignee(s): Shire LLCThe present invention describes compounds, compositions and methods of using the same comprising lysine covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
Patent expiration dates:
- February 24, 2023✓
- August 24, 2023✓
- February 24, 2023
-
Abuse-resistant amphetamine prodrugs
Patent 7,662,788
Issued: February 16, 2010
Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Robert & Piccariello; Thomas & Paul; Bernhard J. & Verbicky; Christopher A.
Assignee(s): Shire LLCThe invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
Patent expiration dates:
- February 24, 2023✓
- August 24, 2023✓
- February 24, 2023
-
Abuse-resistant amphetamine prodrugs
Patent 7,671,030
Issued: March 2, 2010
Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Robert & Piccariello; Thomas & Paul; Bernhard J. & Verbicky; Christopher A.
Assignee(s): Shire LLCThe invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
Patent expiration dates:
- February 24, 2023✓✓
- August 24, 2023✓
- February 24, 2023
-
Abuse-resistant amphetamine prodrugs
Patent 7,671,031
Issued: March 2, 2010
Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Robert & Piccariello; Thomas & Paul; Bernhard J. & Verbicky; Christopher A.
Assignee(s): Shire LLCThe invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
Patent expiration dates:
- February 24, 2023✓
- August 24, 2023✓
- February 24, 2023
-
Abuse-resistant amphetamine prodrugs
Patent 7,674,774
Issued: March 9, 2010
Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Robert & Piccariello; Thomas & Paul; Bernhard J. & Verbicky; Christopher A.
Assignee(s): Shire LLCThe invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
Patent expiration dates:
- February 24, 2023✓✓
- February 24, 2023✓✓
- August 24, 2023✓
- February 24, 2023
-
Abuse-resistant amphetamine prodrugs
Patent 7,678,770
Issued: March 16, 2010
Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Robert & Piccariello; Thomas & Paul; Bernhard J. & Verbicky; Christopher A.
Assignee(s): Shire LLCThe invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
Patent expiration dates:
- February 24, 2023✓
- February 24, 2023✓
- August 24, 2023✓
- February 24, 2023
-
Abuse-resistant amphetamine prodrugs
Patent 7,678,771
Issued: March 16, 2010
Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Robert & Piccariello; Thomas & Paul; Bernhard J. & Verbicky; Christopher A.
Assignee(s): Shire LLCThe invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
Patent expiration dates:
- February 24, 2023✓
- February 24, 2023✓✓
- February 24, 2023✓✓
- August 24, 2023✓
- February 24, 2023
-
Abuse-resistant amphetamine prodrugs
Patent 7,687,466
Issued: March 30, 2010
Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Robert & Piccariello; Thomas & Paul; Bernhard J. & Verbicky; Christopher A.
Assignee(s): Shire LLCThe invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
Patent expiration dates:
- February 24, 2023✓
- August 24, 2023✓
- February 24, 2023
-
Abuse-resistant amphetamine prodrugs
Patent 7,687,467
Issued: March 30, 2010
Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Robert & Piccariello; Thomas & Paul; Bernhard J. & Verbicky; Christopher A.
Assignee(s): Shire LLCThe invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
Patent expiration dates:
- February 24, 2023✓✓
- February 24, 2023✓✓
- August 24, 2023✓
- February 24, 2023
-
Abuse-resistant amphetamine prodrugs
Patent 7,700,561
Issued: April 20, 2010
Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Robert & Piccariello; Thomas & Paul; Bernhard J. & Verbicky; Christopher A.
Assignee(s): Shire LLCThe invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
Patent expiration dates:
- February 24, 2023✓
- August 24, 2023✓
- February 24, 2023
-
Abuse-resistant amphetamine prodrugs
Patent 7,713,936
Issued: May 11, 2010
Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Robert & Piccariello; Thomas & Paul; Bernhard J. & Verbicky; Christopher A.
Assignee(s): Shire LLCThe invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
Patent expiration dates:
- February 24, 2023✓
- August 24, 2023✓
- February 24, 2023
-
Abuse-resistant amphetamine prodrugs
Patent 7,718,619
Issued: May 18, 2010
Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Robert & Piccariello; Thomas & Paul; Bernhard J. & Verbicky; Christopher A.
Assignee(s): Shire LLCThe invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
Patent expiration dates:
- February 24, 2023✓✓
- February 24, 2023✓✓
- August 24, 2023✓
- February 24, 2023
-
Abuse-resistant amphetamine prodrugs
Patent 7,723,305
Issued: May 25, 2010
Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Robert & Piccariello; Thomas & Paul; Bernhard J. & Verbicky; Christopher A.
Assignee(s): Shire LLCThe invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
Patent expiration dates:
- February 24, 2023✓✓
- February 24, 2023✓✓
- August 24, 2023✓
- February 24, 2023
More about Vyvanse (lisdexamfetamine)
- Side effects
- Drug interactions
- Dosage information
- During pregnancy or Breastfeeding
- Reviews (872)
- Patient tips
- Drug images
- Compare alternatives
- Pricing & coupons
- En español
- Drug class: CNS stimulants
- FDA approval history
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
